The PBS NewsHour on Friday featured an interview of Anthony Fauci, director of the NIH National Institute of Allergy and Infectious Diseases (NIAID), by Senior Correspondent Ray Suarez, in which they discussed an FDA panel’s recommendation that the antiretroviral Truvada be approved for pre-exposure prophylaxis (PrEP) to prevent HIV among healthy people at risk of contracting the virus. If approved, Truvada “can be potentially very effective” as a prevention modality among specific populations at high risk of contracting HIV, Fauci said, according to the interview. Fauci also discussed the medication’s cost and concerns about adherence to the drug regimen, PBS notes (Suarez, 5/11).